April 14- U.S. drugstore chain operator Walgreen Co is under pressure from a group of shareholders to consider relocating to Europe to gain tax benefits, the Financial Times reported.» Read More
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
A break down on the latest activity in mergers and acquisitions, with CNBC's David Faber.
Of the new drugs approved from 2004 through 2011, Quintiles was involved with 85 percent of the central nervous system drugs, 76 percent of oncology drugs and 72 percent of cardiovascular drugs. Mad Money host Jim Cramer explains why the stock is a buy.
Technical analyst Jeff Tomasulo is bearish on Pfizer after its big drop today. Fundamental analyst Pat Dorsey also isn't a buyer. (2:25)
CNBC's Andrea Day reports Swiss drug maker Novartis is disputing allegations in 2 U.S. federal lawsuits. The company is accused of wining and dining doctors.
Isis Pharmaceuticals CEO Stanley Crooke discusses his new technology Antisense and its role in helping huntington's disease.
The pharmaceutical and medical devices company reported quarterly earnings and revenue Tuesday that exceeded Wall Street's expectations as growth of newer medicines for cancer, hepatitis C and blood clots offset declining sales of its treatments for heartburn and attention deficit disorder.
The "astonishing" growth of the middle class in emerging markets is benefiting General Mills and creating jobs in the U.S., CEO Ken Powell told CNBC's "Street Signs" on Thursday.
Not every stock needs to have a "turbo-charged" growth angle to it. Mad Money host Jim Cramer says big pharma stocks have been red hot, and discusses which ones are worth owning.
Investors should always have a high yielding stock in their portfolio. Big pharma stocks tend to do better when the economy isn't doing so well, explains Mad Money host Jim Cramer. A preview of Johnson & Johnson ahead of earnings.
Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
The government says big pharma should not be allowed to pay generic drug makers to let them keep their costly branded drugs on the market longer, reports CNBC's Bertha Coombs.
CNBC's Seema Mody reports the latest from the Nasdaq: Drug makers Actavis and AstraZeneca reach an agreement to launch a Crestor generic in 2016.
AstraZeneca settled a patent dispute with generic drug maker Watson Laboratories over its cholesterol drug Crestor, reports CNBC's Bertha Coombs.
One sector that is yet to be truly tapped in Africa is the brewing industry, according to research firm Bernstein Research, which believes it is probably the most attractive region for long-term profit growth for global brewers.
Sometimes, when a stock surges on an analyst upgrade, it's high time to make a bearish bet. That's exactly what one big options trader did on Walgreen.
After a difficult January, when shoppers first felt the effect of a payroll tax hike that lowered take-home pay by 2 percent, some retailers got a little relief in February from growing employment and a rising stock market.
Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.
Moves by Indonesia's President Susilo Bambang Yudhoyono to put his finance minister in charge of the central bank is leading to concerns that he may be seeking someone more malleable to run the state coffers in the run up to next year's elections.